Literature DB >> 11004612

Cicatricial pemphigoid.

T E Fleming1, N J Korman.   

Abstract

UNLABELLED: Cicatricial pemphigoid (CP) is a heterogeneous group of rare, chronic, subepithelial blistering disorders of the mucous membranes and, occasionally, the skin, which can have serious and rarely fatal consequences. The most common clinical features are desquamative gingivitis, oral erosions, and conjunctival fibrosis. Skin lesions occur less frequently and may present as widespread vesicles and bullae, as in bullous pemphigoid (BP). In some patients, the scarring can be a source of significant morbidity because it can result in odynophagia, strictures of the upper aerodigestive tract, or corneal opacities leading to eventual blindness. This article is a comprehensive review and discusses clinical, pathologic, and pathophysiologic aspects of this group of disorders collectively known as CP. (J Am Acad Dermatol 2000;43:571-91.) LEARNING
OBJECTIVE: At the conclusion of this learning activity, participants should be familiar with the clinical spectrum of CP, the histopathologic and immunopathologic characteristics, the differential diagnosis, the treatment, and the natural history of the disease. Furthermore, this learning activity should facilitate early diagnosis of CP and should promote the idea that the involvement of other specialists, including ophthalmologists, otolaryngologists, gastroenterologists, and oral medicine specialists, as appropriate, will aid in providing these patients with the highest quality of care.

Entities:  

Mesh:

Year:  2000        PMID: 11004612     DOI: 10.1067/mjd.2000.107248

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  18 in total

1.  Erosive Vulvovaginitis.

Authors:  Jack D. Sobel
Journal:  Curr Infect Dis Rep       Date:  2003-12       Impact factor: 3.725

2.  [Mycophenolate mofetil as effective therapy option in scarring pemphigoid].

Authors:  I Elser; D Selimovic; T Ruzicka; A Kuhn; M Megahed
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

Review 3.  Autoimmune subepidermal bullous skin diseases: the impact of recent findings for the dermatopathologist.

Authors:  Roberto Verdolini; Rino Cerio
Journal:  Virchows Arch       Date:  2003-06-11       Impact factor: 4.064

4.  [Topical immunomodulators: a therapeutic option for oral cicatricial pemphigoid].

Authors:  T Assmann; T Burchardt; J Becker; T Ruzicka; M Megahed
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

5.  Relationship between target antigens and major histocompatibility complex (MHC) class II genes in producing two pathogenic antibodies simultaneously.

Authors:  L R Zakka; D B Keskin; P Reche; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

Review 6.  Autoimmune bullous diseases: ocular manifestations and management.

Authors:  Caroline Laforest; Shyamala C Huilgol; Robert Casson; Dinesh Selva; Igal Leibovitch
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Comparison of reactivity and epitope recognition between sera from American and Italian patients with oral pemphigoid.

Authors:  M Mignogna; A Lanza; L Rossiello; V Ruocco; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

8.  Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin.

Authors:  N Sami; K C Bhol; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

9.  Mucous membrane pemphigoid in a patient with chronic hepatitis B virus infection: A case report.

Authors:  Christine Yi-Ting Chou; Chi-Wei Lin; Gwo-Shing Chen; Ru-Yi Huang
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

Review 10.  [Mucous membrane pemphigoid with ocular involvement. Part I: Clinical manifestations, pathogenesis and diagnosis].

Authors:  E Schmidt; T Meyer-Ter-Vehn; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-03       Impact factor: 1.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.